ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Sanofi-Aventis (Suisse) SA - Revaxis, suspension injectable
0064601
Revaxissuspension injectable
J07CA01Diphtheria-Poliomyelitis-Tetanus
10.08.2000  
Composition
toxoidum tetani min. 20 U.I., toxoidum diphtheriae min. 2 U.I., virus poliomyelitis typus 1 inactivatus 29 U., virus poliomyelitis typus 2 inactivatus 7 U., virus poliomyelitis typus 3 inactivatus 26 U., aluminium 0.35 mg ut aluminii hydroxidum hydricum ad adsorptionem, formaldehydum, medium 199 cum phenylalaninum 12.5 µg, phenoxyethanolum, ethanolum anhydricum 2 mg, acidum hydrochloridum, natrii hydroxidum, acidum aceticum, aqua ad iniectabile, ad suspensionem pro 0.5 ml corresp., kalium 0.12 mg et natrium 1.6 mg, residui: neomycinum, streptomycinum, polymyxinum B.
Packungsbestandteile
Injection suspension 
  
 
Active AgentDose
Toxoidum Diphtheriae2U.I. / 0.5ml
Toxoidum Tetani20U.I. / 0.5ml
BAG: Active AgentDose
Toxoidum Diphtheriae2 UI
Toxoidum Tetani20 UI
Vaccinum Poliomyelitidis Inactivatum (Salk typ I, II, III)62 U
 
Inactive agentsDose
Acetic Acid 
Acidum Hydrochloridum 
Alumine0.35mg / 0.5ml
Cum Phenylalaninum12.5µg / 0.5ml
Ethanol Anhydrate2mg / 0.5ml
Formaldehydum 
Inactivatus26U. / 0.5ml
Medium199
Sodium Hydroxide 
Phenoxyethanol 
Virus Poliomyelitis Typus3
 
Package numberPackage SizeEFPCPCategorySLOut of trade (MedRef)
003 11.8629.30BSLNo
00410PRPRB No
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home